Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-14

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the safety and efficacy of Fabagal® developed by ISU ABXIS Co., Ltd., which has similar efficacy to active comparator (Agalsidase beta).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion

NCT05343715

Fabry Disease

COMPLETED PHASE1

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

NCT00140621

Fabry Disease

COMPLETED PHASE4

Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

NCT00864851

Fabry Disease

COMPLETED PHASE3

A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.

NCT00233870

Fabry Disease

COMPLETED

To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

NCT04143958

Fabry Disease

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is to evaluate the efficacy of Fabagal compared to active comparator (Agalsidase beta). The secondary objectives will evaluate the safety, pharmacokinetics, and immunogenicity of Fabagal compared to active comparator (Agalsidase beta).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fabry Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fabagal® (Agalsidase beta)

1 mg/kg, administered every 2 weeks for 12 months

Group Type EXPERIMENTAL

Fabagal® (Agalsidase beta)

Intervention Type BIOLOGICAL

1 mg/kg every 2 weeks for 12 months

Active Comparator (Agalsidase beta)

1 mg/kg, administered every 2 weeks for 12 months

Group Type ACTIVE_COMPARATOR

Active comparator (Agalsidase beta)

Intervention Type DRUG

1 mg/kg every 2 weeks for 12 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fabagal® (Agalsidase beta)

1 mg/kg every 2 weeks for 12 months

Intervention Type BIOLOGICAL

Active comparator (Agalsidase beta)

1 mg/kg every 2 weeks for 12 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Those who have been diagnosed with Fabry disease by genetic and alpha-galactosidase A enzyme tests and grouped by sex are as follows:

* Male: Those who have confirmed GLA mutation (variation of α-galactosidase A gene) by genetic testing, and whose activity of alpha-galactosidase A in leukocytes is 5% or less than the normal mean value
* Female: Those who have confirmed GLA mutation by genetic testing, and whose alpha-galactosidase A is within the normal range or is deficient
2. Age: Those who are aged 8 years or older
3. Those who have at least one of the following symptoms and signs:

* For 24 hr urinary protein extraction (\>4 mg/m2/hr) or for spot urinary protein/creatinine ratio (≥200 mg/g \[Cr\]) \*Pediatrics: Aged \<19 years

* Abnormal left ventricular function as evidenced by MRI or echocardiography

* Left ventricular mass index (LVMI)\* \>115 g/m2 (male), \>95 g/m2 (female) or
* Left ventricular wall thickness \>12 mm (However, in the case of patients with hypertension, patients must have blood pressure treatment for at least 6 months prior to administration of the same drug) etc.

* Clinically significant arrhythmias and conduction disturbances, etc.

* Stroke or transient ischemic attack, etc., as evidenced by objective testing
4. Patients who have not previously received enzyme replacement therapy (ERT) or Chaperone therapy for treatment of Fabry disease
5. Patients who voluntarily consented and signed the informed consent form
6. Patients (female patients and partners of male patients who are of childbearing potential) who have agreed to use a medically appropriate method of contraception (intrauterine device, condoms, surgical methods such as vasectomy) during the clinical study

Exclusion Criteria

1. Patients who participated in other studies in which investigational products are administered within 30 days prior to the screening visit
2. Patients with chronic kidney disease stage 4 to 5 (CKD 4-5; see Section 16.1)
3. Patients who are currently on dialysis or have a history of kidney transplantation, or patients scheduled for dialysis at the time of screening, or waitlisted for kidney transplantation
4. Patients who have started angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) treatment within 4 weeks prior to the screening visit or whose dose has been changed
5. Patients who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the clinical study
6. Patients with a history of HIV, hepatitis B/C or HIV antibodies, hepatitis B surface antigens, or hepatitis C antibodies
7. Patient whose medical, emotional, behavioral, or psychological conditions appear to interfere with compliance with the requirements of the clinical study according to the investigator's judgment

Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No